The Hindu : Ranbaxy's anti-AIDS drugs in WHO list

Online edition of India's National Newspaper
Thursday, Jul 11, 2002

Business

Business

Ranbaxy's anti-AIDS drugs in WHO list

NEW DELHI JULY 10. Ranbaxy Laboratories, India's largest pharmaceutical company, today announced that its anti-AIDs drugs, Zidovudine 300mg tablets, Nevirapine 200mg tablets, Lamivudine 150mg tablets and Lamivudine 150 plus, Zidovudine 300mg tablets have been granted approval by the World Health Organisation (WHO).

These products are now under the purview of WHO approved list of anti-AIDs drugs, according to a release.

Ranbaxy will now become a pre-qualified supplier of these products to the U.N. agency. These products will be manufactured at the company's plant at Dewas (Central India) which has been approved by WHO, U.S. FDA, U.K. MCA, South Africa-MCC, and Australian-TGA.

The company has developed a range of generic anti retrovirals (ARVs). It markets its anti-AIDs range of products in several countries. African governments have shown interest in sourcing ARVs from Ranbaxy.

In the Indian market, at present, there are ten products available with more in the pipeline.

With this, Ranbaxy can offer sufficient drugs to construct several first line HAART (highly active anti retroviral therapy) regimens.

The company has one of the largest range of bio-equivalent generic ARVs, namely, danosine, Lamivudine, Lamivudine plus Stavudine, Lamivudine plus Zidovudine, Stavudine, Zidovudine.

Printer friendly page
Send this article to Friends by E-Mail

Business